Houston, Texas, Jul 02, 2020 (Newsfile Corp via COMTEX) -- Houston, Texas--(Newsfile Corp. - July 2, 2020) - The obesity issue is bursting at the seams.
In fact, according to the World Health Organization, at least 2.8 million people die every year from being either overweight or obese.
Worse, such issues lead to chronic diseases, including cardiovascular diseases (mainly heart disease and stroke), diabetes, musculoskeletal disorders (especially osteoarthritis - a highly disabling degenerative disease of the joints); and some cancers (including endometrial, breast, ovarian, prostate, liver, gallbladder, kidney, and colon).
On top of that, it costs the world up to $64 billion a year to treat cardiovascular events. It costs another $87 billion to treat diabetes worldwide. Worse, it costs the world $16 billion a year to help treat obesity.
However, the world may soon get the solution it needs to help treat such issues, stemming from being obese or overweight with psilocybin.
That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."
Researching the issue is Yield Growth's majority owned subsidiary NeonMind.
In fact, the company just filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin or psilocin (or analogs thereof) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
It did so to protect the invention that the administration of psilocin or psilocybin results in overall weight loss in individuals by:
reducing food cravings;
counteracting compulsive overeating; and
improving quality of diet by empowering the mind to select lower calorie foods with greater nutritional value.
The pending patent also covers the use of micro dose administration of psilocin or psilocybin or both compounds to have the additional weight loss effects of:
treating or regulating diabetes,
regulating blood glucose, and
reducing susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity.
In addition, the company engaged TLS, which is a contract research organization, to conduct analytical testing and pre-clinical/clinical testing and obtain Health Canada approval for its planned clinical trials.